FCER1A

Across TCGA pan-cancer cohorts, FCER1A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FCER1A data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FCER1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FCER1A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, LGG, and SARC are the cancer types where FCER1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.227	0.618	.008	18	view →
LGG	OS	Median	All	0.134	0.811	<.001	12	view →
SARC	OS	Median	All	0.205	0.839	<.001	12	view →
SKCM	OS	Median	III,IV	0.939	0.668	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FCER1A–LUSC (OS)

Open the LUSC breakdown →